Literature DB >> 6150368

Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes.

J B McCormick, J P Getchell, S W Mitchell, D R Hicks.   

Abstract

The in-vitro effect of ribavirin on the replication of lymphadenopathy-associated virus (LAV), one of the prototype viruses aetiologically associated with lymphadenopathy syndrome and acquired immunodeficiency syndrome, was tested. Ribavirin, a nucleoside, suppressed the replication of LAV in cultures of human adult T lymphocytes. Suppression occurred at ribavirin concentrations of 50 micrograms/ml or higher.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome--prevention and control; Clinical Research; Diseases; Drugs; Hiv Infections; In Vitro; Research Methodology; Treatment; Viral Diseases

Mesh：

Substances：

Year:  1984        PMID： 6150368     DOI： 10.1016/s0140-6736(84)92060-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  [AIDS and HTLV-III in West Germany: the status February 1985].

Authors:  R Hehlmann; V Erfle; G Hunsmann; R Kurth
Journal:  Klin Wochenschr       Date:  1985-05-02

5.  AIDS and taurolin.

Authors:  P Bayardelle
Journal:  CMAJ       Date:  1986-03-01       Impact factor: 8.262

Review 6.  A guide to the investigation and treatment of patients with AIDS and AIDS-related disorders.

Authors:  F A Shepherd; M M Fanning; R Duperval; J M Dupuy; B Garvey; J Joncas; N LaPointe; R Morisset
Journal:  CMAJ       Date:  1986-05-01       Impact factor: 8.262

7.  Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

Authors:  J Balzarini; L Naesens; P Herdewijn; I Rosenberg; A Holy; R Pauwels; M Baba; D G Johns; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells.

Authors:  H Nakashima; S Harada; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

9.  Treatment of the acquired immune deficiency syndrome.

Authors:  S Gupta; M S Gottlieb
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

10.  Cyclosporine-induced deterioration in patients with AIDS.

Authors:  A Phillips; M A Wainberg; R Coates; M Klein; A Rachlis; S Read; F Shepherd; H Vellend; S Walmsley; P Halloran
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.